Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Governance of Diabetes Management in Non-specialistic Hospital Settings

22 de dezembro de 2015 atualizado por: Ivana Zavaroni, Azienda Ospedaliero-Universitaria di Parma
The prevalence of diabetes among inpatients in medical wards, surgery and intensive care units in Italy is approximatively 12-25%. The management of in hospital diabetes and hyperglycemia is complex and requires a specific training for physicians and nurses in non-specialist settings. The overall project aims at the implementation of a "best practice" model of care for hospitalized diabetic patients in non-specialist settings.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

The project aims at defining a model of care for hospitalized diabetic patients in non-specialist settings based on the national and international recommendations. This is a cluster randomized study to evaluate the efficacy of a structured education training program for physicians and nurses in improving an ad hoc composite performance score of diabetes management and some clinical outcomes. The study will be carried out in 6 hospitals of the Emilia-Romagna region in Italy and it will involve 3 different wards (internal medicine, intensive care unit, surgery). For each hospital one intervention and two controls wards will be randomly identified.

At baseline the clinical management of patients with stress hyperglycemia/diabetes will be assessed in all participating wards over a 3-month period. Then, a structured educational program regarding the management of stress hyperglycemia/diabetes in the inpatient setting will be carried out only in the intervention wards. This program will last 2 months. Health care professionals also will be trained in the regular use of appropriate management tools (hyperglycemia dedicated standard operation procedures, audits, etc.).

Three months after the end of the educational program, the 3-month assessment of clinical management of patients with stress hyperglycemia/diabetes will be repeated in all participating wards.

The assessment of clinical management of stress hyperglycemia/diabetes will be based on a set of clinical performance indicators concerning 5 major domains (admission assessment, glucose monitoring, medical therapy, management of consults, management of discharge). These indicators will be used to define a composite performance score of appropriateness and efficacy. The highest score (1) will be assigned when the indicator is monitored, the lowest (0) when the indicator will be not detected, according to the scoring method previously reported by Rossi et al. Therefore, the score of each domain will range between 0 and the number of indicators used to assess appropriateness and efficacy of that domain.

Domain 1 - Initial assessment: score 0-5

  • records of admission glycemia
  • records of fasting plasma glucose
  • records of HbA1c
  • appropriate diagnosis of stress hyperglycemia/diabetes mellitus according to ADA
  • records of history of presence/absence of pharmacological diabetes therapy

Domain 2 - Glucose monitoring: score 0-4

  • appropriate glucose monitoring: at least 80% of three daily preprandial glycemia or, in critically ill patients, monitoring according to the specific algorithm used in the ward
  • presence and use of specific forms for glucose records
  • presence of ward standing orders to recognize and correct hypoglycemia
  • presence of ward standing orders to monitor and manage glucose in critically ill patients (Critically ill patients are defined as patients who require intensive care for acute critical illnesses, such as myocardial infarction, stroke, septic shock or severe respiratory failure, requiring intensive or semi-intensive therapy and, as a rule, not taking food orally during the first 24-72 hours)

Domain 3 - Medical therapy: score 0-2

  • records of time and dose of insulin therapy
  • interruption of Metformin therapy when indicated (correct indications to discontinuation of Metformin therapy were: any critical illness, acute renal, cardiac and/or respiratory failure, surgery or iodinated contrast agents administration.)

Domain 4 - Consults: score 0-2

  • request and records of diabetes specialist consult
  • request and records of nursing consult

Domain 5 - Management of discharge: score 0-3

  • planning of diabetes follow-up visit after hospitalization
  • patient education for home blood glucose self-monitoring
  • patient education for all other aspects of diabetes management

The sum of the scores of each domain from 1 to 5 is the composite performance score.

The following clinical outcomes will be recorded both at baseline and 3 months after the end of the educational program in all participating wards.:

  • all hypoglycemic events (blood glucose ≤ 70 mg/dl)
  • severe hypoglycemic events (blood glucose ≤ 40 mg/dl with or without clouding of consciousness)
  • difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
  • achievement of glycemic goals: 4 consecutive blood glucose levels ≤ 130 mg/dl (preprandial) or ≤ 180 mg/dl (postprandial), or 4 consecutive blood glucose levels between 140 and 180 mg/dl in critically ill patients
  • survival
  • discharge condition: a score of 0 will be assigned in case of death or transfer to a higher intensity ward and score 1 in all other cases, i.e. home discharge or transferral to a lower intensity ward.

Tipo de estudo

Intervencional

Inscrição (Real)

1449

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Bologna, Itália
        • AUSL Ospedale Maggiore
      • Ferrara, Itália, 44121
        • Azienda Ospedaliero-Universitaria
      • Modena, Itália
        • AUSL Carpi
      • Parma, Itália, 43126
        • Azienda Ospedaliero-Universitaria Parma
      • Piacenza, Itália, 29121
        • AUSL Piacenza
      • Reggio Emilia, Itália, 42027
        • AUSL Montecchio

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • patients with type 2 or type 1 diabetes or stress hyperglycemia

Exclusion Criteria:

  • age <18,
  • patients hospitalized for diabetic complications: ketoacidosis, hyperosmolar syndrome, hypoglycemic coma, pregnant diabetics or gestational diabetes

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: educational training
implementation of a structured educational program for physicians and nurses
Sem intervenção: no educational training
no educational training wards

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Composite performance score computed as the sum of the performance scores of all 5 domains of appropriateness and efficacy in both the intervention and the control wards
Prazo: 11 months
Efficacy of educational training will be evaluated as absolute change of the performance scores after the intervention compared to baseline in the two groups
11 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
hypoglycemic events in the intervention and control wards
Prazo: 11 months
rate difference of hypoglycemia events (blood glucose ≤ 70 mg/dl) in the intervention and control wards
11 months
severe hypoglycemic events in the intervention and control wards
Prazo: 11 months
rate difference of severe hypoglycemia events (blood glucose ≤ 40 mg/dL with or without clouding of consciousness) in the intervention and control wards
11 months
difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
Prazo: 11 months
difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
11 months
achievement of glycemic goals in the intervention and control wards
Prazo: 11 months
number of patients that achieve glycemic goals: 4 consecutive blood glucose levels ≤ 130 mg/dl (preprandial) or ≤ 180 mg/dl (postprandial), or 4 consecutive blood glucose levels between 140 and 180 mg/dl in critically ill patients
11 months
survival rate during hospitalization in the intervention and control wards
Prazo: 11 months
survival rate during hospitalization (score 1 for survival, score 0 for death)
11 months
discharge condition in the intervention and control wards
Prazo: 11 months
a score of 0 will be assigned in case of death or transfer to a higher intensity ward and score 1 in all other cases, i.e. home discharge or transferral to a lower intensity ward.
11 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Ivana Zavaroni, MD, Azienda Ospedaliero-Universitaria Parma

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de janeiro de 2012

Conclusão Primária (Real)

1 de março de 2015

Conclusão do estudo (Real)

1 de março de 2015

Datas de inscrição no estudo

Enviado pela primeira vez

19 de novembro de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de dezembro de 2015

Primeira postagem (Estimativa)

29 de dezembro de 2015

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

29 de dezembro de 2015

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de dezembro de 2015

Última verificação

1 de dezembro de 2015

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • AOParma

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever